Aspirin's effectiveness in cancer prevention has been a topic of debate, and a recent study by Monash University has shed new light on this issue. The study, published in JAMA Oncology, reveals a surprising finding: daily low-dose aspirin is not the cancer-fighting hero we once thought it was for older adults. In fact, it may even increase their risk of cancer mortality.
The Aspirin Paradox: A Double-Edged Sword?
This research followed over 19,000 participants from Australia and the US, and the results are eye-opening. After a median treatment period of 4.7 years, the study found that low-dose aspirin had no significant impact on overall cancer incidence. Moreover, it 'significantly' increased the risk of cancer mortality by 15% compared to the placebo group.
But here's where it gets controversial: the elevated cancer mortality risk observed during the original ASPREE trial period seemed to dissipate in the post-trial ASPREE-eXTension study. This suggests that the aspirin's effect may not be long-lasting.
Dr. Michael Tam, a member of the RACGP Expert Committee - Quality Care, describes this study as highly relevant for GPs. 'It provides an important insight that directly impacts our practice,' he said.
The ASPREE project, a two-part study, included a randomized, blinded, placebo-controlled clinical trial from 2010 to 2017, where participants were given either a daily 100 mg dose of aspirin or a placebo. The second part, the ASPREE-eXTension study, was an observational phase from 2018 to 2024, where participants stopped taking the aspirin or placebo.
Associate Professor Suzanne Orchard, the study's first author, noted, 'There was no overall change in cancer incidence among those assigned low-dose aspirin, but the elevated cancer mortality risk is a concern.'
Prior studies, mostly focused on middle-aged adults, suggested that aspirin reduced cancer risk after 10 years, particularly for colorectal cancer. However, the Monash study's findings suggest that this may not be the case for older adults.
Dr. Tam believes that while aspirin's benefits for colorectal cancer prevention, especially for those at high risk, are still valid, the question of when to stop preventive medications for older adults remains.
'This study supports the idea that aspirin should not be continued indefinitely for cancer prevention in older adults,' he said.
So, what do you think? Is aspirin's role in cancer prevention overstated for older adults? Should we reconsider our approach to preventive medications for this age group? Share your thoughts in the comments below!
